EUROFINS CEREP-REGR (ALECR.PA) Stock Price & Overview
EPA:ALECR • FR0013256518
Current stock price
The current stock price of ALECR.PA is 15800 EUR. Today ALECR.PA is up by 2.6%. In the past month the price decreased by -14.13%. In the past year, price increased by 135.82%.
ALECR.PA Key Statistics
- Market Cap
- 158M
- P/E
- 11.13
- Fwd P/E
- N/A
- EPS (TTM)
- 1,419.54
- Dividend Yield
- N/A
ALECR.PA Stock Performance
ALECR.PA Stock Chart
ALECR.PA Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to ALECR.PA. When comparing the yearly performance of all stocks, ALECR.PA is one of the better performing stocks in the market, outperforming 95.41% of all stocks.
ALECR.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to ALECR.PA. Both the profitability and the financial health of ALECR.PA get a neutral evaluation. Nothing too spectacular is happening here.
ALECR.PA Earnings
ALECR.PA Forecast & Estimates
ALECR.PA Groups
Sector & Classification
ALECR.PA Financial Highlights
Over the last trailing twelve months ALECR.PA reported a non-GAAP Earnings per Share(EPS) of 1419.54. The EPS increased by 18.19% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 17.1% | ||
| ROA | 9.27% | ||
| ROE | 10.76% | ||
| Debt/Equity | 0 |
ALECR.PA Ownership
ALECR.PA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| DIM | SARTORIUS STEDIM BIOTECH | 36.25 | 18.366B | ||
| SRT3 | SARTORIUS AG-VORZUG | 41.98 | 17.881B | ||
| 56S1 | SARTORIUS STEDIM BIOTECH | 35.3 | 17.695B | ||
| SRT | SARTORIUS AG | 33.01 | 14.092B | ||
| QIA | QIAGEN N.V. | 15.83 | 7.285B | ||
| 1SXP | SCHOTT PHARMA AG& CO KGAA | 14.21 | 2.353B | ||
| EVT | EVOTEC SE | N/A | 1.003B | ||
| GXI | GERRESHEIMER AG | 8.33 | 736.393M | ||
| FF | FINE FOODS & PHARMACEUTICALS | 14.9 | 207.364M | ||
| MLC | MALIN CORP PLC | N/A |
Related stock screener links
View all stocks in the Life Sciences Tools & Services Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Paris Exchange | Find stocks with similar TA and Setup ratings on the EuroNext exchanges | Find stocks with similar Fundamental rating on the EuroNext exchanges | Find the competitors with the best technical ratings on the EuroNext exchanges | Find the competitors with the best fundamentals on the EuroNext exchanges | Find the competitors with the best valuation on the EuroNext exchanges | Find the competitors with the best dividend on the EuroNext exchanges | Find the competitors with the best analyst ratings on the EuroNext exchanges
About ALECR.PA
Company Profile
Eurofins-Cerep SA engages in the provision of preclinical drug research services. The company is headquartered in Celle-Levescault, Nouvelle-Aquitaine and currently employs 207 full-time employees. The company went IPO on 2010-03-19. The Company, using its BioPrint technology systems that analyzes pharmaceutical drugs on the market, those that have been withdrawn, and those that failed in the development stages, builds up predictive models of the potential of new drugs. These predictions are based on the drugs' chemical structure and their performance in vitro. The firm then offers solutions to the pharmaceutical and biotechnology sectors on reducing time and costs in the early stages of the drug development process. Clients can also gain access to some of the Company's technology by subscribing to BioPrint. The Company’s maximum revenue is generated through Exports accounts.
Company Info
IPO: 2010-03-19
EUROFINS CEREP-REGR
Le Bois l'Eveque
Celle-Levescault NOUVELLE-AQUITAINE FR
Employees: 207
Phone: 33549893000
EUROFINS CEREP-REGR / ALECR.PA FAQ
What does EUROFINS CEREP-REGR do?
Eurofins-Cerep SA engages in the provision of preclinical drug research services. The company is headquartered in Celle-Levescault, Nouvelle-Aquitaine and currently employs 207 full-time employees. The company went IPO on 2010-03-19. The Company, using its BioPrint technology systems that analyzes pharmaceutical drugs on the market, those that have been withdrawn, and those that failed in the development stages, builds up predictive models of the potential of new drugs. These predictions are based on the drugs' chemical structure and their performance in vitro. The firm then offers solutions to the pharmaceutical and biotechnology sectors on reducing time and costs in the early stages of the drug development process. Clients can also gain access to some of the Company's technology by subscribing to BioPrint. The Company’s maximum revenue is generated through Exports accounts.
What is the stock price of EUROFINS CEREP-REGR today?
The current stock price of ALECR.PA is 15800 EUR. The price increased by 2.6% in the last trading session.
What is the dividend status of EUROFINS CEREP-REGR?
ALECR.PA does not pay a dividend.
How is the ChartMill rating for EUROFINS CEREP-REGR?
ALECR.PA has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Which stock exchange lists ALECR stock?
ALECR.PA stock is listed on the Euronext Paris exchange.
What is the employee count for ALECR stock?
EUROFINS CEREP-REGR (ALECR.PA) currently has 207 employees.
Can you provide the market cap for EUROFINS CEREP-REGR?
EUROFINS CEREP-REGR (ALECR.PA) has a market capitalization of 158.00M EUR. This makes ALECR.PA a Micro Cap stock.